Lumosa Therapeutics Co., Ltd

Shanghai Lumosa Therapeutics Co., Ltd.

David Chih-Kuang Chou

Jin-Ding Huang

Shu-Wen Kuo

Yu-En Tien

Shin-Jr Tsai

Chan-Jung Li

Shin Tsai

The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysine linking arm, and a pharmaceutical acceptable carrier. The composition has a pH less than 6.5, preferably has a pH about pH 2-5.5 The composition may comprise a pharmaceutical acceptable excipient such as mannitol, sorbitol, sucrose, lactose, or trehalose.

Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate

The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.

Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester

Growing community of inventors

Palo Alto, CA, United States of America

David Chih-Kuang Chou